Mostrar el registro sencillo del ítem

Forecast Alzheimer's disease progression to better select patients for clinical trials

dc.rights.licenseopenen_US
dc.contributor.authorMAHEUX, Etienne
dc.contributor.authorORTHOLAND, Juliette
dc.contributor.authorBIRKENBIHL, Colin
dc.contributor.authorTHIBEAU-SUTRE, Elina
dc.contributor.authorSOOD, Meemansa
dc.contributor.authorARCHETTI, Damiano
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBOUTELOUP, Vincent
dc.contributor.authorKOVAL, Igor
dc.contributor.authorDURRLEMAN, Stanley
dc.date.accessioned2022-06-20T10:21:54Z
dc.date.available2022-06-20T10:21:54Z
dc.date.issued2021-07
dc.date.conference2021-07-18
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/140283
dc.description.abstractEnObjectives Subject recruitment is a burden that hampers clinical trials, especially in neurodegenerative diseases, where worsening of abilities is subtle, long-term and heterogeneous. Targeting the right patients during trial screening is a way to reduce the needed sample size or conversely to improve the proven effect size. Methods From Alzheimer’s disease (AD) observational cohorts, we selected longitudinal data that matched AD trials (inclusion and exclusion criteria, trial duration and primary endpoint). We modeled EMERGE, a phase 3 trial in pre-clinical AD, and a mild AD trial, using 4 research cohorts (ADNI, Memento, PharmaCog, AIBL). For each patient, we simulated its treated counterpart by applying an individual treatment effect. It consisted in a linear improvement of outcome for effective decliners, calibrated on our data so to match the expected trial effect size. Next, we built a multimodal AD course map that grasped long-term disease progression in a mixed-effects fashion [1] with Leaspy. We used it to forecast never-seen individuals’ outcomes from their screening biomarkers. Based on these individual screening predictions, we selected clinically relevant sub-groups [2]. Finally, we compared the effective sample size that would have been needed for the trial, with and without our selections. We evaluated dispersion of this metric using a bootstrap procedure. Results In all investigated setups and cohorts, we found a decrease in needed sample sizes with selection. For EMERGE trial, we showed that selecting patients having a predicted CDR-SoB changed between 0.5 and 1.5 points per year enabled to reduce the needed sample size by 38.2 ± 3.3 %. For the mild AD trial, we showed that selecting patients having a predicted MMSE changed between 1 and 2 points per year enabled to reduce the needed sample size by 38.9 ± 2.2 %. Conclusions We build a modelling framework for forecasting individual outcomes from their multimodal screening assessments. Using them as an extra inclusion criterion in clinical trials, we can better control trial population and thus reduce the needed sample size for a given treatment effect.
dc.language.isoENen_US
dc.title.enForecast Alzheimer's disease progression to better select patients for clinical trials
dc.typeCommunication dans un congrès avec actesen_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.countryfren_US
bordeaux.title.proceedingISCB 2021: 42nd Conference of the International Society for Clinical Biostatisticsen_US
bordeaux.conference.cityOnlineen_US
bordeaux.peerReviewedouien_US
hal.identifierhal-03483237
hal.version1
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.date=2021-07&rft.au=MAHEUX,%20Etienne&ORTHOLAND,%20Juliette&BIRKENBIHL,%20Colin&THIBEAU-SUTRE,%20Elina&SOOD,%20Meemansa&rft.genre=proceeding


Archivos en el ítem

ArchivosTamañoFormatoVer

No hay archivos asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem